Stacy Ann Coen - Aug 2, 2023 Form 4 Insider Report for ImmunoGen, Inc. (IMGN)

Role
SVP & CHIEF BUSINESS OFFICER
Signature
/s/ Renee Lentini, Attorney-in-Fact
Stock symbol
IMGN
Transactions as of
Aug 2, 2023
Transactions value $
-$1,030,520
Form type
4
Date filed
8/4/2023, 07:33 PM
Previous filing
Jul 5, 2023
Next filing
Aug 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMGN Common Stock Options Exercise $20.9K +4.26K +38.82% $4.92 15.2K Aug 2, 2023 Direct
transaction IMGN Common Stock Sale -$77.1K -4.26K -27.97% $18.12 11K Aug 2, 2023 Direct F1
transaction IMGN Common Stock Options Exercise $395K +80.3K +732.9% $4.92 91.3K Aug 4, 2023 Direct
transaction IMGN Common Stock Sale -$1.37M -80.3K -87.99% $17.05 11K Aug 4, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Stock Option (Right to Buy) Options Exercise $0 -4.26K -1.64% $0.00 256K Aug 2, 2023 Common Stock 4.26K $4.92 Direct F3
transaction IMGN Stock Option (Right to Buy) Options Exercise $0 -80.3K -31.41% $0.00 175K Aug 4, 2023 Common Stock 80.3K $4.92 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.01 to $18.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
F3 Exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.